IOTA, KinaseDetect, SARomics partner to accelerate drug discovery

Kinase production, kinase assay development, kinase crystal structure determination, kinase fragment library construction, hit finding and optimization, in silico screening, kinase biochemical and biophysical screening, structure- and ligand-based drug design and medicinal chemistry services are all included within a single offering.

KinaseDetect director Olaf-Georg Issinger said structure-based drug design in combination with fragment-based lead discovery is a powerful combination in modern drug discovery.

"We are collaborating with IOTA Pharmaceuticals and SARomics Biostructures in developing a service platform which will greatly accelerate the drug discovery process for this important class of drugs," Issinger said.

IOTA Pharmaceuticals director and co-founder David Bailey said fragment-based drug discovery at IOTA combines identification of fragments with high ligand efficiency with the power of structure-based drug design, rapidly optimizing ligand binding and selectivity in drug-like molecules.

"The KINOMED Partnership between KinaseDetect, SARomics and IOTA will develop these leads to produce a new generation of kinase therapeutics," Bailey said.

IOTA Pharmaceuticals’ activities completely span the hit finding and lead optimization stages of drug development, and include target analysis, focused fragment library construction, in silico screening, biochemical and biophysical screening, structure- and ligand-based design and medicinal chemistry services.

KinaseDetect offers recombinant protein kinases to pharmaceutical companies and academic customers.

SARomics Biostructures is a Scandinavian provider of structural biology and in silico drug discovery services. The company accelerates its customers’ drug discovery processes by providing contract R&D support in the areas of protein crystallization, X-ray protein structure determination, NMR spectroscopy and computational chemistry.